

Edwards Lifesciences Corp  
Form 8-K  
June 07, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) June 6, 2018**

**EDWARDS LIFESCIENCES CORPORATION**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**1-15525**  
**(Commission**

**file number)**

**36-4316614**  
**(IRS Employer**

**Identification No.)**

**One Edwards Way, Irvine, California**  
**(Address of principal executive offices)**

**(949) 250-2500**

**92614**  
**(Zip Code)**

**Registrant's telephone number, including area code**

N/A

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On June 6, 2018, Edwards Lifesciences Corporation priced and entered into an underwriting agreement (the Underwriting Agreement ) to issue and sell, subject to certain conditions, \$600,000,000 aggregate principal amount of 4.300% senior unsecured notes due 2028 pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.

The above description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

The following exhibits are included with this Current Report on Form 8-K.

(d) **Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
1.1	<u>Underwriting Agreement, dated as of June 6, 2018, by and among Edwards Lifesciences Corporation and Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated and J.P. Morgan Securities LLC, for themselves and as representatives of the several underwriters listed in Schedule A therein.</u>
12.1	<u>Computation of Ratio of Earnings to Fixed Charges</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 7, 2018

**EDWARDS LIFESCIENCES CORPORATION**

By: /s/ Scott B. Ullem  
Scott B. Ullem  
Chief Financial Officer